Cenicriviroc is primarily used in the treatment of inflammatory and fibrotic diseases, particularly those affecting the liver. It is being investigated for its potential to treat non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage due to fat accumulation. By targeting and inhibiting specific chemokine receptors, it helps reduce inflammation and fibrosis, slowing the progression of liver disease. Additionally, its dual-action mechanism makes it a promising candidate for addressing other chronic inflammatory conditions where these receptors play a key role.